Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 2
1976 1
1977 2
1978 2
1979 7
1980 11
1981 8
1982 6
1983 6
1984 6
1985 14
1986 18
1987 16
1988 10
1989 7
1990 9
1991 10
1992 12
1993 15
1994 22
1995 19
1996 18
1997 14
1998 15
1999 19
2000 15
2001 20
2002 15
2003 18
2004 19
2005 26
2006 26
2007 33
2008 43
2009 36
2010 35
2011 35
2012 33
2013 37
2014 22
2015 34
2016 35
2017 19
2018 25
2019 28
2020 52
2021 52
2022 51
2023 36
2024 24

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

934 results

Results by year

Filters applied: . Clear all
Page 1
Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology.
Pirazzini M, Rossetto O, Eleopra R, Montecucco C. Pirazzini M, et al. Among authors: montecucco c. Pharmacol Rev. 2017 Apr;69(2):200-235. doi: 10.1124/pr.116.012658. Pharmacol Rev. 2017. PMID: 28356439 Free PMC article. Review.
Seronegative autoimmune diseases: A challenging diagnosis.
Lenti MV, Rossi CM, Melazzini F, Gastaldi M, Bugatti S, Rotondi M, Bianchi PI, Gentile A, Chiovato L, Montecucco C, Corazza GR, Di Sabatino A. Lenti MV, et al. Among authors: montecucco c. Autoimmun Rev. 2022 Sep;21(9):103143. doi: 10.1016/j.autrev.2022.103143. Epub 2022 Jul 15. Autoimmun Rev. 2022. PMID: 35840037 Review.
Mapping and predicting mortality from systemic sclerosis.
Elhai M, Meune C, Boubaya M, Avouac J, Hachulla E, Balbir-Gurman A, Riemekasten G, Airò P, Joven B, Vettori S, Cozzi F, Ullman S, Czirják L, Tikly M, Müller-Ladner U, Caramaschi P, Distler O, Iannone F, Ananieva LP, Hesselstrand R, Becvar R, Gabrielli A, Damjanov N, Salvador MJ, Riccieri V, Mihai C, Szücs G, Walker UA, Hunzelmann N, Martinovic D, Smith V, Müller CS, Montecucco CM, Opris D, Ingegnoli F, Vlachoyiannopoulos PG, Stamenkovic B, Rosato E, Heitmann S, Distler JHW, Zenone T, Seidel M, Vacca A, Langhe E, Novak S, Cutolo M, Mouthon L, Henes J, Chizzolini C, Mühlen CAV, Solanki K, Rednic S, Stamp L, Anic B, Santamaria VO, De Santis M, Yavuz S, Sifuentes-Giraldo WA, Chatelus E, Stork J, Laar JV, Loyo E, García de la Peña Lefebvre P, Eyerich K, Cosentino V, Alegre-Sancho JJ, Kowal-Bielecka O, Rey G, Matucci-Cerinic M, Allanore Y; EUSTAR group. Elhai M, et al. Among authors: montecucco cm. Ann Rheum Dis. 2017 Nov;76(11):1897-1905. doi: 10.1136/annrheumdis-2017-211448. Epub 2017 Aug 23. Ann Rheum Dis. 2017. PMID: 28835464
Botulinum neurotoxins.
Rossetto O, Megighian A, Scorzeto M, Montecucco C. Rossetto O, et al. Among authors: montecucco c. Toxicon. 2013 Jun 1;67:31-6. doi: 10.1016/j.toxicon.2013.01.017. Epub 2013 Feb 19. Toxicon. 2013. PMID: 23435262 Review. No abstract available.
Botulism.
Johnson EA, Montecucco C. Johnson EA, et al. Among authors: montecucco c. Handb Clin Neurol. 2008;91:333-68. doi: 10.1016/S0072-9752(07)01511-4. Handb Clin Neurol. 2008. PMID: 18631849 No abstract available.
Presynaptic enzymatic neurotoxins.
Rossetto O, Morbiato L, Caccin P, Rigoni M, Montecucco C. Rossetto O, et al. Among authors: montecucco c. J Neurochem. 2006 Jun;97(6):1534-45. doi: 10.1111/j.1471-4159.2006.03965.x. J Neurochem. 2006. PMID: 16805767 Free article. Review.
Neurotoxins affecting neuroexocytosis.
Schiavo G, Matteoli M, Montecucco C. Schiavo G, et al. Among authors: montecucco c. Physiol Rev. 2000 Apr;80(2):717-66. doi: 10.1152/physrev.2000.80.2.717. Physiol Rev. 2000. PMID: 10747206 Free article. Review.
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial.
Humby F, Durez P, Buch MH, Lewis MJ, Rizvi H, Rivellese F, Nerviani A, Giorli G, Mahto A, Montecucco C, Lauwerys B, Ng N, Ho P, Bombardieri M, Romão VC, Verschueren P, Kelly S, Sainaghi PP, Gendi N, Dasgupta B, Cauli A, Reynolds P, Cañete JD, Moots R, Taylor PC, Edwards CJ, Isaacs J, Sasieni P, Choy E, Pitzalis C; R4RA collaborative group. Humby F, et al. Among authors: montecucco c. Lancet. 2021 Jan 23;397(10271):305-317. doi: 10.1016/S0140-6736(20)32341-2. Lancet. 2021. PMID: 33485455 Free PMC article. Clinical Trial.
934 results